Results 211 to 220 of about 11,994 (242)
Some of the next articles are maybe not open access.
Mycoses (Berlin), 2022
Rezafungin, a new echinocandin with an extended half‐life, exhibits potent activity against Candida spp. Aside from the MIC, specific interactions between antifungal and isolate, including the duration of anti‐infective activity, may impact dose interval
C. Carvalhaes +4 more
semanticscholar +1 more source
Rezafungin, a new echinocandin with an extended half‐life, exhibits potent activity against Candida spp. Aside from the MIC, specific interactions between antifungal and isolate, including the duration of anti‐infective activity, may impact dose interval
C. Carvalhaes +4 more
semanticscholar +1 more source
Micafungin: the US perspective
Expert Review of Anti-infective Therapy, 2005Invasive fungal infections cause considerable morbidity and mortality in nosocomial settings and amongst immunocompromised hosts. Invasive candidiasis and aspergillosis remain the most common invasive fungal infections, with Candida spp. constituting the fourth most common bloodstream infection in the USA.
Aimee K. Zaas, William J. Steinbach
openaire +3 more sources
Micafungin: a therapeutic review
Expert Review of Anti-infective Therapy, 2004In recent decades, the incidence of aspergillosis, candidiasis and clinically important deep mycoses has been increasing, with advances in transplantation medicine and anticancer chemotherapy. Micafungin (FK463, Fujisawa Healthcare) has been developed as a novel type of antifungal agent, which inhibits 1,3-beta-D-glucan synthase in the fungal cell wall.
Yasuhito Higashiyama, Shigeru Kohno
openaire +3 more sources
An in-vitro comparative study of the binding of caspofungin and micafungin to plasma proteins.
The Journal of pharmacy and pharmacology, 2021OBJECTIVES Echinocandins are widely used for the treatment of invasive fungal diseases. While they bind strongly to plasma proteins, our knowledge of this process is not sufficient to permit their pharmacokinetics and pharmacodynamics targets to be ...
K. Yamasaki +6 more
semanticscholar +1 more source
Mycoses, 2012
SummaryInvasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21st century as it is active against Candida species, Aspergillus ...
Dimitrios P. Kontoyiannis +2 more
openaire +2 more sources
SummaryInvasive fungal infections have emerged as a major cause of increased morbidity and mortality among severely immunosuppressed patients with haematological malignancy. Micafungin, a new member of the echinocandin class, is a valuable addition to the antifungal armamentarium of the 21st century as it is active against Candida species, Aspergillus ...
Dimitrios P. Kontoyiannis +2 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 2020
BACKGROUND Echinocandin resistance rarely occurs in clinical Candida parapsilosis isolates and the underlying mechanism is unknown. OBJECTIVES To determine the prevalence of echinocandin resistance and the underlying mechanism for a large collection of
A. Arastehfar +12 more
semanticscholar +1 more source
BACKGROUND Echinocandin resistance rarely occurs in clinical Candida parapsilosis isolates and the underlying mechanism is unknown. OBJECTIVES To determine the prevalence of echinocandin resistance and the underlying mechanism for a large collection of
A. Arastehfar +12 more
semanticscholar +1 more source
Micafungin - The newest echinocandin
Drugs of Today, 2009Micafungin is one of three currently FDA-approved echinocandins. It has potent in vitro activity against Candida species including non-albicans Candida and azole-resistant Candida species and has also demonstrated clinical efficacy against deep-seated Candida infections. Additional in vitro data and preliminary clinical efficacy studies suggest that it
Zelalem Temesgen +2 more
openaire +3 more sources
Therapeutic Drug Monitoring, 2021
Supplemental Digital Content is Available in the Text. Background: In this study, the authors aimed to compare the pharmacokinetics (PK) of micafungin in critically ill patients receiving continuous venovenous hemofiltration (CVVH, 30 mL·kg−1·h−1) with ...
Nicolas Garbez +10 more
semanticscholar +1 more source
Supplemental Digital Content is Available in the Text. Background: In this study, the authors aimed to compare the pharmacokinetics (PK) of micafungin in critically ill patients receiving continuous venovenous hemofiltration (CVVH, 30 mL·kg−1·h−1) with ...
Nicolas Garbez +10 more
semanticscholar +1 more source
Micafungin for the treatment of invasive aspergillosis
Journal of Infection, 2014Invasive aspergillosis is a major cause of morbidity and mortality in immunocompromised patients, particularly those with neutropenia and those undergoing bone marrow or stem cell transplants. Micafungin is an echinocandin antifungal drug with activity against all major Candida spp.
Enoch, D. A. +5 more
openaire +3 more sources
Role of Micafungin in the Antifungal Armamentarium
Current Medicinal Chemistry, 2007Serious infections caused by opportunistic molds remain a major problem for public health. Immune deficiency following organ transplantation and aggressive cancer treatment has greatly increased the incidence of systemic mycoses, and invasive aspergillosis in patients with AIDS is associated with significant morbidity and mortality.
Hidenori Ohki +7 more
openaire +3 more sources